Remove Compliance Remove Containment Remove Development Remove Drug Delivery
article thumbnail

CS acquires AxeroVision’s dry eye disease pipeline

Drug Discovery World

CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes.

article thumbnail

14th Annual Pre-Filled Syringes and Drug Devices 2022

pharmaphorum

The Future of Drug Delivery and Combination Product Device Design. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five key drug discovery deals of summer 2023

Drug Discovery World

Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops.”

Drugs 52
article thumbnail

XPhyto Announces RT-PCR Test for Point-of-Care COVID-19 Detection

The Pharma Data

“Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. . “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA. . VANCOUVER, BC / ACCESSWIRE / October 28, 2020 / XPhyto Therapeutics Corp.

RNA 52
article thumbnail

BetterLife Closes Acquisition of Second Generation Psychedelic Assets of Transcend Biodynamics LLC

The Pharma Data

With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.

article thumbnail

BetterLife Pharma Strengthens Board of Directors

The Pharma Data

is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. About BetterLife Pharma Inc.

article thumbnail

BetterLife Confirms Non-controlled Status of 2-bromo-LSD with Health Canada

The Pharma Data

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that Health Canada has confirmed that 2-bromo-LSD is not a controlled substance. VANCOUVER, Jan.